RITUXAN for Low-grade or Follicular (Indolent) Non-Hodgkin’s Lymphoma
RITUXAN® is a monoclonal antibody that has been used by thousands of patients with certain types of NHL for over a decade. It specifically targets a marker (called CD20) on the B-cells in which most types of non-Hodgkin’s lymphoma (NHL) start. For low-grade or follicular (indolent) NHL, RITUXAN may be an effective part of treatment. It may be used in different ways throughout the course of the disease:
-
Adding RITUXAN to CVP chemotherapy is a commonly used follicular NHL treatment.
Learn more
RITUXAN® is indicated for the treatment of patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy.
-
After CVP chemotherapy, RITUXAN Ongoing Therapy may be taken for low-grade NHL for up to 2 years.
Learn more
RITUXAN® is indicated for the treatment of patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy.
-
For treatment upon relapse—if there is a relapse, RITUXAN may be used alone to treat low-grade or follicular NHL.
Learn more
RITUXAN® is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
“Keeping the records was really important for us, too, for his treatment, because it gave us some of the answers that maybe we’d missed. I went with Rick to the doctor appointments, and I had questions, too. You have to ask questions honestly.” —Susan, Caregiver
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.
INDICATIONS and IMPORTANT SAFETY INFORMATION
RITUXAN® is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Important Safety Information
RITUXAN® can cause serious side effects, some of which can be life-threatening, including: progressive multifocal leukoencephalopathy (PML), infusion reactions, tumor lysis syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.
Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.
Please read the Medication Guide in HTML or PDF versions and the full prescribing information for more information.
